First blood test to diagnose Alzheimer's disease to be available in US starting late June
The first blood test to help diagnose Alzheimer's disease will be available from late June in the US following regulatory clearance for its use last week, according to the Japanese company behind the innovation.
The test will initially be available at about 50 American research institutes and hospitals that specialise in Alzheimer's disease, Goki Ishikawa, head of Fujirebio Holdings, a unit of Japan's H.U. Group Holdings, said in an interview Tuesday. It's partnering with bigger rivals like Beckman Coulter to help develop and manufacture their products, he said.
The Food and Drug Administration cleared the blood test to help diagnose Alzheimer's disease last week, potentially making it easier to find and treat patients with the memory-robbing disease that affects nearly 7 million Americans.
The test was cleared for use in people at least 55 years old and who exhibit signs of the disease. It is designed to detect amyloid, a protein that can build up in the brain and is a hallmark of Alzheimer's, the most common form of dementia in the elderly.
The process, which takes roughly 30 minutes from drawing the blood to diagnosis, will be available to patients at a fraction of the cost of a PET scan. The method is viewed as a critical step in making new types of Alzheimer's treatments widely accessible.
Until now, patients typically have to get a specialised PET scan to detect amyloid in their brains or undergo cerebrospinal fluid tests, both of which are more expensive and invasive. The lack of quick and easy tests has until now slowed the roll-out of new Alzheimer's drugs like Eisai and Biogen's Leqembi and Eli Lilly's Kisunla.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South China Morning Post
8 hours ago
- South China Morning Post
As Japan's birth rate falls to a record low, a ‘critical' demographic crisis unfolds
Japan is facing a severe demographic crisis, marked by a historic low in its birth rate alongside a rapidly ageing population. In 2024, the number of babies born in the country fell to 686,061, marking the first time this figure has dropped below 700,000 since record-keeping began in 1899, according to a health ministry announcement on Wednesday. Births dropped by 41,227, or 5.7 per cent, from the previous year. It was only two years ago, in 2022, that the figure fell below the 800,000 birth threshold. A ministry official said the situation was 'critical' as 'multiple complex factors are preventing individuals from fulfilling their hopes of marriage and starting families,' The Asahi newspaper reported. The country's demographic crisis is advancing 15 years ahead of experts' predictions, who had forecast around 755,000 births for 2024, and did not anticipate that births would fall below 690,000 until 2039. Additionally, Japan's total fertility rate – the average number of children a woman is expected to have in her lifetime – dropped to a historic low of 1.15, down from 1.20 the previous year, underscoring the country's ongoing trend of delayed marriage and childbirth. Both the birth and fertility rates have decreased for nine consecutive years. The figures exclude foreign nationals born in Japan and Japanese born outside the country. Japan also saw a record high of 1,605,298 deaths in 2024, a 1.9 per cent increase from the previous year. This led to a population loss of 919,237 people, marking the 18th consecutive year of decline and the largest recorded.
South China Morning Post
11 hours ago
- South China Morning Post
How a pacemaker, smaller than a grain of rice, could revolutionise cardiac medicine
A new, tiny pacemaker, smaller than a grain of rice, could play a big role in the future of medicine, according to the engineers who developed it. Researchers at Northwestern University in the US state of Illinois unveiled the device, which they say is the smallest pacemaker in the world, in a study published in the peer-reviewed medical journal Nature. The device is still years away from being used in humans, but it could eventually be useful for infants with congenital heart defects and for adults, the researchers say. 'I think it's really exciting technology that will change how electrical stimulation is done,' says Igor Efimov, a Northwestern experimental cardiologist who co-led the study. Play The device – which is just 1.8mm (1/16th of an inch) wide, 3.5mm long and 1mm thick – can be inserted with a catheter or syringe.
The Standard
a day ago
- The Standard
Drug test kits to be introduced in schools next academic year to combat ‘space oil' abuse
Download The Standard app to stay informed with news, updates, and significant events - The upgraded app is now available on both iOS and Android platforms.
